Dolutegravir Based Regimens
-
Congress Data
The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, DolutegravirThe Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir
DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, DolutegravirDTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
DTG+3TC: GEMINI 144-Week Data
An Update from HIV GLASGOW 2020
Nneka Nwokolo, Senior Global Medical DirectorDTG+3TC: GEMINI 144-Week Data
An Update from HIV GLASGOW 2020
Nneka Nwokolo, Senior Global Medical Director
DTG+3TC: TANGO 96-Week Data
An Update from HIV GLASGOW 2020
Jose Gatell, Senior Global Medical DirectorDTG+3TC: TANGO 96-Week Data
An Update from HIV GLASGOW 2020
Jose Gatell, Senior Global Medical Director
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir -
Clinical Trials Data
The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, DolutegravirThe Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
DTG+3TC: GEMINI 144-Week Data
An Update from HIV GLASGOW 2020
Nneka Nwokolo, Senior Global Medical DirectorDTG+3TC: GEMINI 144-Week Data
An Update from HIV GLASGOW 2020
Nneka Nwokolo, Senior Global Medical Director
DTG+3TC: TANGO 96-Week Data
An Update from HIV GLASGOW 2020
Jose Gatell, Senior Global Medical DirectorDTG+3TC: TANGO 96-Week Data
An Update from HIV GLASGOW 2020
Jose Gatell, Senior Global Medical Director
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir -
Dosing
Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director
Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director -
Pharmacokinetics
Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director
Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director -
Safety
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir -
Virology/Resistance
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research -
Real World Evidence
Dovato Real World Evidence Video
Dr. Benjamin Young, Head of Global Medical Directors
Dovato Real World Evidence Video
Dr. Benjamin Young, Head of Global Medical Directors
DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, DolutegravirDTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Connect With Our Medical Experts
Find My ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Talk to a Medical Expert
Connect now with a live ViiV Medical Expert.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Contact Us
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1‑888‑226‑8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch